About: SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigen

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigen Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigen
Creator	Wang, Lichun Cao, Han Wang, Yunfei Liu, Cunbao
Source	Medline; PMC
abstract	Since its emergence in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has developed into a global pandemic within a matter of months. While subunit vaccines are one of the prominent options for combating coronavirus disease 2019 (COVID‐19), the immunogenicity of spike protein‐based antigens remains unknown. When immunized in mice, the S1 domain induced much higher IgG and IgA antibody levels than the RBD and more efficiently neutralized SARS‐CoV‐2 when adjuvanted with alum. It is inferred that a large proportion of these neutralization epitopes are located in the S1 domain but outside the RBD and that some of these are spatial epitopes. This finding indicates that expression systems with posttranslational modification abilities are important to maintain the natural configurations of recombinant spike protein antigens and are critical for effective COVID‐19 vaccines. Further, adjuvants prone to a Th1 response should be considered for S1‐based subunit COVID‐19 vaccines to reduce the potential risk of antibody‐dependent enhancement (ADE) of infection. This article is protected by copyright. All rights reserved.
has issue date	2020-07-21(xsd:dateTime)
bibo:doi	10.1002/jmv.26320
bibo:pmid	32691875
has license	no-cc
sha1sum (hex)	fe38bf4b1634ae92335ae8169cb300c5665ea67f
schema:url	https://doi.org/10.1002/jmv.26320
resource representing a document's title	SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigen
has PubMed Central identifier	PMC7404424
has PubMed identifier	32691875
schema:publication	J Med Virol
resource representing a document's body	covid:fe38bf4b1634ae92335ae8169cb300c5665ea67f#body_text
is schema:about of	named entity 'global' named entity 'antigens' named entity 'efficiently' named entity 'MUCH' named entity 'COVID-19' named entity 'ONE OF' named entity 'SARS-CoV-2' named entity 'levels' named entity 'vaccines' named entity 'spike' named entity 'emergence' named entity 'RBD' named entity 'antibody' named entity 'adjuvants' named entity 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'recombinant' named entity 'epitopes' named entity 'COVID-19' named entity 'IgA antibody' named entity 'adjuvanted' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'Th1' named entity 'recombinant proteins' named entity 'SARS-CoV-2' named entity 'inclusion bodies' named entity 'sonication' named entity 'IgG2a' named entity 'RBD' named entity 'epitopes' named entity 'RBD' named entity 'sulfuric acid' named entity 'antibodies' named entity 'immunization' named entity 'serum' named entity 'SARS-CoV-2' named entity 'IgG2a' named entity 'Antibody' named entity 'IgA' named entity 'BSL-3' named entity 'IgA' named entity 'immunization' named entity 'RBD' named entity 'antibodies' named entity 'IgG2a' named entity 'virus' named entity 'E.coli' named entity 'Th1' named entity 'IgG1' named entity 'IgA' named entity 'infection' named entity 'DMEM' named entity 'IgG1' named entity 'Peking Union Medical College' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'IgG2a' named entity 'fusion protein' named entity 'RBD' named entity 'IgG2a' named entity 'ThermoFisher Scientific' named entity 'fusion protein' named entity 'fight infection' named entity 'intramuscularly' named entity 'CAMS' named entity 'mucosal immunity' named entity 'RBD' named entity 'adjuvants' named entity 'RBD' named entity 'IgG' named entity 'RBD' named entity 'COVID-19' named entity 'IgA' named entity 'fusion protein' named entity 'norovirus' named entity 'SARS-CoV-2' named entity 'E.coli' named entity 'PBS' named entity 'immunization'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software